公开(公告)号：US20220370611A1

公开(公告)日：2022-11-24

申请号：US17529450

申请日：2021-11-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  In-Cheol SUN ,  Man Kyu SHIM ,  Ji Woong CHOI

IPC: A61K41/00 ,  A61P35/00 ,  A61K31/351 ,  A61K47/69

Abstract: Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

公开(公告)号：US20230173083A1

公开(公告)日：2023-06-08

申请号：US17735371

申请日：2022-05-03

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Hong Yeol YOON ,  In-Cheol SUN ,  Man Kyu SHIM ,  Hanhee CHO

IPC: A61K47/64 ,  A61K47/65 ,  A61K31/704 ,  A61P35/00

CPC classification number: A61K47/643 ,  A61K31/704 ,  A61K47/65 ,  A61P35/00

Abstract: Disclosed is a prodrug for preventing or treating cancer. The prodrug is mediated by albumin present in the blood to achieve high cancer selectivity for cancer and high stability. Also disclosed is a pharmaceutical composition for preventing or treating cancer including the prodrug. The anticancer prodrug and the pharmaceutical composition form a conjugate with albumin even without using a carrier or delivery vector when injected in vivo. Therefore, the anticancer prodrug and the pharmaceutical composition are effective in preventing or treating cancer, have increased in vivo half-lives, and can accumulate in cancer with increased efficiency to significantly alleviate the side effects of the anticancer drug.

公开(公告)号：US20230293719A1

公开(公告)日：2023-09-21

申请号：US17859078

申请日：2022-07-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  In-Cheol SUN ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: A61K47/69 ,  A61P35/00 ,  A61K47/64

CPC classification number: A61K47/6915 ,  A61K47/64 ,  A61P35/00

Abstract: Disclosed is an optimal peptide-liposome complex capable of multivalent crosslinking with PD-L1 on the cell surface to induce degradation of PD-L1. The peptide-liposome complex effectively blocks PD-L1, an immune checkpoint on the surface of cancer cells, and prevents the recycling of PD-L1 by intracellular metabolism to induce complete degradation of PD-L1 in cancer cells, achieving an increased therapeutic effect on cancer.

公开(公告)号：US20170216460A1

公开(公告)日：2017-08-03

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ju Hee RYU ,  Ick Chan KWON ,  Man Kyu SHIM ,  Hong Yeol YOON

IPC: A61K49/00 ,  G01N33/58 ,  G01N33/574 ,  C07K9/00

CPC classification number: A61K49/0056 ,  A61K47/555 ,  A61K49/0032 ,  A61K49/0052 ,  C07K5/1016 ,  C07K5/1019 ,  C07K9/001 ,  G01N33/57496 ,  G01N33/581 ,  G01N2333/96466

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

公开(公告)号：US20210179681A1

公开(公告)日：2021-06-17

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ju Hee RYU ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: C07K14/47 ,  C07K16/28 ,  A61K47/10 ,  A61P35/00

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.